Suzhou Connect Biopharmaceuticals, Ltd.
HomeحContact UsحSite Map
Suzhou Connect biopharma is a clinical-stage company that discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. We identify and advance our drug candidates through in-house discovery and in-licensing, while leveraging qualified CROs for further development. We successfully completed a phase I clinical trial study on our leading program CBP-307, a novel and selective second generation S1P1 (a G-protein coupled receptor -GPCR) modulator for the treatment of a range of autoimmune disorders, including multiple sclerosis, inflammatory bowel disease and psoriasis.  The randomized, double-blind, placebo controlled study assessed the tolerability, pharmacokinetics and pharmacodynamics of CBP-307 in Melbourne Australia, and CBP-307 exhibited excellent safety features and potent T cell modulation activity as well as optimal pharmacokinetics and pharmacodynamics profiles,  demonstrating the best-in-class potential. Meanwhile, we are advancing other preclinical programs including CBP-174 and
Connect Biopharmaceuticals Receives Approval to Initiate Clinical Trials of CBP-307 in China
Connect Biopharmaceuticals Completes $25 Million Financing to Advance Clinical Development of Novel Immune Modulators
Connect Biopharma CEO Invited to Attend the CABS Investor Forum 2016 in San Francisco During the Week of the JP Morgan Healthcare Conference
Suzhou Connect Biopharma Reports Positive Phase 1b Result for Novel S1P1 Modulator CBP-307 for Autoimmune Diseases
Suzhou Connect Biopharma Reports Positive Phase 1a Results for CBP-307, a Novel, Orally-active S1P1 Modulator for Autoimmune Diseases
Copyright: Suzhou Connect Biopharmaceuticals, Ltd.